Phase 2 Liver Cancer Trial, Recruiting NCT07157969 Sponsor: Peking Union Medical College Hospital Condition: Liver Cancer
Back to Liver Cancer

Phase 2 Liver Cancer Trial, Recruiting

NCT07157969
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily, sign a consent form, and attend follow-up appointments as required.
  • People aged 18 or older at the time of signing the consent form, of any gender.
  • People who have been diagnosed with hepatocellular carcinoma (a type of liver cancer) confirmed by medical imaging, tissue sample, or cell sample.
  • People whose liver cancer is classified as BCLC Stage B or C (intermediate or advanced stage).
  • People who have at least one tumour that can be measured using standard imaging criteria (RECIST 1.1).
  • People whose general physical functioning is rated at 0 or 1 on the ECOG scale, meaning they are fully active or have only minor limitations in physical activity.
  • People whose liver function is rated as Child-Pugh class A or B, meaning the liver is still functioning at a moderate to reasonable level.
  • People with a life expectancy of at least 3 months.
  • People with adequate blood count and organ function levels (confirm with trial site for specific values).

Who may not be able to join:

  • People whose liver cancer may be treatable with surgery aimed at a complete cure, or who have already had such surgery with no remaining measurable tumour, or who have had or are planned to have a liver transplant.
  • People who are currently pregnant or breastfeeding.
  • People with a known allergy or intolerance to a type of immunotherapy medication called a PD-1/PD-L1 monoclonal antibody.
  • People who have received certain local or regional liver treatments within the 4 weeks before starting the trial, including surgery, radiation therapy, or procedures targeting the liver's blood supply or tumour directly.
  • People who have had a different type of cancer in the past 5 years, other than the hepatocellular carcinoma being studied.
  • People who have serious wounds that have not healed, active ulcers, or fractures that have not been treated.
  • People with an active autoimmune disease or a history of autoimmune conditions (conditions where the immune system attacks the body's own tissues).
  • People with a significant history of serious gastrointestinal (digestive system) disease (confirm with trial site for specific conditions).
  • People with a significant history of serious heart or stroke-related disease (confirm with trial site for specific conditions).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 86-18601989848

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
19 February 2025
Est. completion
1 June 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

ORR, objective response rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov